CN105560869A - Medicine composition for treating schizophrenia and preparation method thereof - Google Patents

Medicine composition for treating schizophrenia and preparation method thereof Download PDF

Info

Publication number
CN105560869A
CN105560869A CN201610047276.4A CN201610047276A CN105560869A CN 105560869 A CN105560869 A CN 105560869A CN 201610047276 A CN201610047276 A CN 201610047276A CN 105560869 A CN105560869 A CN 105560869A
Authority
CN
China
Prior art keywords
weight portion
pharmaceutical composition
ethanol
weight
percent concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610047276.4A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610047276.4A priority Critical patent/CN105560869A/en
Publication of CN105560869A publication Critical patent/CN105560869A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Abstract

The invention discloses a medicine composition for treating child cerebral palsy and a preparation method thereof. The medicine composition is prepared fromlysimachia hemsleyana, sheareria nana, stevioside, aerides odoratum and sanggenone D, can be prepared into various dosage forms according to a conventional preparation process and has a remarkable treatment effect on treating child cerebral palsy.

Description

Pharmaceutical composition for the treatment of cerebral palsy of children and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of cerebral palsy of children and preparation method thereof.
Background technology
Cerebral Palsy in Children refers to children's at period from prenatal to postnatal because of cerebral lesion, makes the syndrome that brain spinoneural function out of hand is then lost.Its main clinical manifestation is central motion obstacle and abnormal posture, and what have can with mental retardation, aphasis, epilepsy, audio visual obstacle etc.Belong to the category of motherland's medical science/myopathy 0.Its morbidity is not enough with natural endowment, deficiency of kidney yang, and brains lose supports; The breast food imbalance day after tomorrow, deficiency-weakness of spleen-QI, infects the mistake of the muscles and bones such as evil poison and supports relevant.Its main pathology shows as atrophy of cerebral cortex in various degree, and gyrus narrows, and brain ditch is obviously broadening, and infracortical protein has loose change, even form blister cavities.Under mirror, show as neurocyte decreased number, and have degeneration.The position of pathological changes determines the basis of clinical symptoms and sign, even if there is above typing neither completely reliably, because infant often shows as the symptom of mixed type.The type of pathological changes is determined according to distinctive symptom.Can be divided into spasm type, athetosis type, ataxia type, tetanic type and mixed type five kinds according to its clinical manifestation, and spasm type is the most common.The diseased region of spasm type is mainly at cerebral cortex and tractus pyramidalis; The diseased region of athetosis type is at brain substrate tuberal part; The diseased region of ataxia type is in cerebellum; The pathological changes impact scope of tetanic type is comparatively wide, and with cerebral cortex, precentral gyrus place is main; Mixed type exists for common with spasm type and the merging of athetosis type.
Fingernail is blue: this product is the blue Sedireasubparishii(Tsi of the orchid family Calanthe plant short stem calyx ridge) herb of E.A.Chr. [HygrochilussubparishiiTsi].The whole year all can adopt, using fresh herb.[nature and flavor] bitter in the mouth; Cool in nature.[function cures mainly] clearing heat for calming endogenous wind.Main infantile convulsion wind.[former phytomorph] short stem calyx ridge is blue, perennial evergreen draft of growing nonparasitically upon another plant.Stem short and oblique on, by pleat phyllopodium surround, grow thickly aerial root in bottom.Aerial root is sturdy and grow, bending, and white, without hair.Leaf 3-5 piece, 2 row, slightly meat, Long Circle or oval shape lanceolar, long 6-12cm, wide 2-3.5cm, tip is blunt or tiltedly and 2 shallowly split, base portion narrows embraces a stem, tool linear slit cylindrarthrosis, and middle veinclearing shows.Scape 1-4, be born in basal part of stem axil; The long 5-17cm of raceme, dredges remaining of raw flower 4-10; Petal sheet oval, long 7-12mm, wide 3-9mm, the blunt circle of tip; Flower pistac; Sepal and petal are closely similar, oblong, long 18-20mm, the wide 7-9mm of the widest part, and slightly meat, carries out, 7, tool arteries and veins, the anxious point of tip, and middle sepal is slightly wide, side sepal and petal narrower, help the carinate wing of tool in the sepal back side; Lip 3 splits, middle sliver meat, long and narrow circle, long 8-10mm, wide about 2mm, and from base portion to the gusset of the high about 1.5mm of tip tool 1 piece, side sliver is upright, the micro-tooth of semicircular edge tool, apart from mouth place tool 1 piece of coniform corpus callosum; Elongation shape, is about 1cm, slightly arc, to protracting; Stamen column length 13-15mm, tool stamen shape wing, rostellum extends 2 and splits, and rostellum handle tip expands; Stick to the pan circle.Capsule oblong, connects handle and is about 7cm.The florescence 5-6 month, fruit phase JIUYUE.Record in Chinese medicine voluminous dictionary.
Lysimachia hemsleyana: this product is the herb of Primulaceae Lysimachia plant Lysimachia hemsleyana LysimachiahemsleyanaMaxim..Summer gathers, and dries.[nature and flavor] micro-hardship; Cool in nature.[function cures mainly] clearing away heat-damp and promoting diuresis; Stimulate the menstrual flow.Main hepatitis; Pyelonephritis; Cystitis; Amenorrhea.Isolate potassium chloride and mixing saccharide in [chemical analysis] herb, preliminary examination still has the reactions such as flavonoid, Saponin, glycoside, lactone and organic acid.[pharmacological action] choleretic effect rat oral 100% Lysimachia hemsleyana decoct 5m1 every day, in continuous 6 weeks, in general anesthesia acute experiment situation, compares with matched group, has the effect promoting bile excretion.As lower in dosage or eye is short with the phase, then act on not obvious, continuous eye decoct is after 2-3 days, and animal feces is thinning, and color becomes sepia, but does not find intoxicating phenomenon.Rat without gallbladder, therefore promotes that the excretion of bile is not caused by enhancing gallbladder contraction.Record in Chinese medicine voluminous dictionary.
Herba Sheareriae: this product is the herb of Compositae Herba Sheareriae platymiscium Herba Sheareriae SheareriananaS.Moore.Summer, autumn gather, magnesium with or dry.[nature and flavor] bitter in the mouth; Property is put down.[function cures mainly] heat-clearing and toxic substances removing; Inducing diuresis to remove edema.Main sore swollen toxin; Edema; Headache due to pathogenic wind-heat.[former phytomorph] annual herb.Stem is upright, high 30 ~ 40 centimetres, the following branch in middle part.Leaf alternate, sparse, linear, long 1 ~ 3 centimetre, wide 2 ~ 3 millimeters, tip point, base portion is narrow, Quan Yuan, stockless.Head inflorescence is little, and top is raw; Flower minority; Involucre is bell, bract 2 layers, and outer bract is extensively avette, and internal layer bract is slightly large; Ligulate flower 3 ~ 4, white, female; Tubular flower 2 ~ 3, both sexes.Achene oblong.Florescence 8 ~ JIUYUE.Record in Chinese medicine voluminous dictionary.
Saliggenon D (SanggenonD): CAS 81422-93-7, molecular formula C 40h 36o 12, molecular weight 708.71.[pharmacological action] resisting hypertension (rat iv, 0.5 ~ 2.0mg/kg); Suppress arachidonic acid metabolism (rat platelet aggregation is concentrated, and suppresses the formation of TXB2, IC50=48.3umo/L); CAMP phosphodiesterase inhibitor (IC50=26gmol/L).[ingredient origin] Cortex Mori Morusalba.
Stevioside (Stevioside): CAS 57817-89-7, molecular formula C 38h 60o 18, molecular weight 804.87.[pharmacological action] blood sugar lowering; Resisting hypertension; Enhance metabolism; Be used for the treatment of hyperchlorhydria.[ingredient origin] Folium Stevlae Rebaudianae Eupatoriumrebaudianum, Folium hydrangeae strigosae Rubussuavissimus.
The structure of 2 crude drug:
Saliggenon D (SanggenonD) stevioside (Stevioside).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment cerebral palsy of children and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment cerebral palsy of children are:
Lysimachia hemsleyana 1100-1200 weight portion Herba Sheareriae 800-900 weight portion stevioside 60-80 weight portion fingernail blue 500-560 weight portion Saliggenon D 40-50 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of cerebral palsy of children, be made up of the crude drug of following weight portion:
Blue 530 weight portion Saliggenon D 45 weight portions of Lysimachia hemsleyana 1150 weight portion Herba Sheareriae 850 weight portion stevioside 70 weight portion fingernail.
Treat a pharmaceutical composition for cerebral palsy of children, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for cerebral palsy of children, it is characterized in that the treatment cerebral palsy of children medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of cerebral palsy of children, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Lysimachia hemsleyana 1100-1200 weight portion Herba Sheareriae 800-900 weight portion stevioside 60-80 weight portion fingernail blue 500-560 weight portion Saliggenon D 40-50 weight portion;
Preparation method:
(1) Lysimachia hemsleyana is got by crude drug proportioning, Herba Sheareriae, stevioside, fingernail is blue, Saliggenon D, mixing, with weight percent concentration 37% ethanol as solvent, extract at 34 DEG C of warm macerating, extraction time is 30 times, each extraction time is 4.5 hours, each solvent load is 25 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by HP-20 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting HP-20 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 81% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 95% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 95% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Preferably treat a preparation method for the pharmaceutical composition of cerebral palsy of children, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: blue 530 weight portion Saliggenon D 45 weight portions of Lysimachia hemsleyana 1150 weight portion Herba Sheareriae 850 weight portion stevioside 70 weight portion fingernail;
Preparation method:
(1) Lysimachia hemsleyana is got by crude drug proportioning, Herba Sheareriae, stevioside, fingernail is blue, Saliggenon D, mixing, with weight percent concentration 37% ethanol as solvent, extract at 34 DEG C of warm macerating, extraction time is 30 times, each extraction time is 4.5 hours, each solvent load is 25 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by HP-20 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting HP-20 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 81% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 95% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 95% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Treat a preparation method for the pharmaceutical composition of cerebral palsy of children, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of cerebral palsy of children, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat cerebral palsy of children medicine.
Medicine composite for curing cerebral palsy of children is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of cerebral palsy of children and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cerebral palsy of children are: Lysimachia hemsleyana 1150g Herba Sheareriae 850g stevioside 70g fingernail blue 530g Saliggenon D 45g;
Preparation method:
(1) Lysimachia hemsleyana is got by crude drug proportioning, Herba Sheareriae, stevioside, fingernail is blue, Saliggenon D, mixing, with weight percent concentration 37% ethanol as solvent, extract at 34 DEG C of warm macerating, extraction time is 30 times, each extraction time is 4.5 hours, each solvent load is 25 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by HP-20 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting HP-20 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 81% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 95% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 95% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 2: pharmaceutical composition for the treatment of cerebral palsy of children and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cerebral palsy of children are: Lysimachia hemsleyana 1100g Herba Sheareriae 900g stevioside 60g fingernail blue 560g Saliggenon D 40g;
Preparation method:
(1) Lysimachia hemsleyana is got by crude drug proportioning, Herba Sheareriae, stevioside, fingernail is blue, Saliggenon D, mixing, with weight percent concentration 37% ethanol as solvent, extract at 34 DEG C of warm macerating, extraction time is 30 times, each extraction time is 4.5 hours, each solvent load is 25 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by HP-20 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting HP-20 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 81% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 95% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 95% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 3: pharmaceutical composition for the treatment of cerebral palsy of children and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cerebral palsy of children are: Lysimachia hemsleyana 1200g Herba Sheareriae 800g stevioside 80g fingernail blue 500g Saliggenon D 50g;
Preparation method:
(1) Lysimachia hemsleyana is got by crude drug proportioning, Herba Sheareriae, stevioside, fingernail is blue, Saliggenon D, mixing, with weight percent concentration 37% ethanol as solvent, extract at 34 DEG C of warm macerating, extraction time is 30 times, each extraction time is 4.5 hours, each solvent load is 25 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by HP-20 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting HP-20 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 81% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 95% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 95% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 321g, adds starch 179g, mixing, granulates, dry, adds microcrystalline Cellulose 67g, magnesium stearate 3.0g, and mixing, is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 252g, adds starch 158g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 217g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 23g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 5 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.4cm apart from liquid level, drips speed with per minute 46 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of cerebral palsy of children
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cerebral palsy of children are:
Blue 1555 weight portion Saliggenon D 42 weight portions of Lysimachia hemsleyana 1119 weight portion fingernail.
Embodiment 8: the pharmaceutical composition for the treatment of cerebral palsy of children
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cerebral palsy of children are:
Blue 1534 weight portion Saliggenon D 46 weight portions of stevioside 72 weight portion fingernail.
Embodiment 9: the pharmaceutical composition for the treatment of cerebral palsy of children
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cerebral palsy of children are:
Blue 1560 weight portion Saliggenon D 51 weight portions of stevioside 75 weight portion fingernail.
Experimental example 1: the experimental study for the treatment of cerebral palsy of children
1 physical data
Infant 16 example is treated altogether, wherein man 9 example, female 7 example, 1 month-3 months 6 age example, 3 months-6 months 6 examples, more than 6 months 4 examples from April ,-2011 in February, 2010.
2 clinical manifestations
Most infant has the medical history of neonatal hypoxia ischemia when producing, antenatal have or have amniotic fluid 3 degree pollution without following intrauterine distress river, have after life or without blue asphyxia or asphyxia pallida history gynecological give oxygen uptake suction sputum artificial respiration etc. rescue after breathing still to moan complexion cyanosis, to have or without tic, suck the breast poor, have a medical check-up visible: body temperature does not rise normal to irritant reaction difference dyspnea anterior fontanelle door tension force or increases, extremity muscular strength and hypomyotonia prestige normal or hyperfunction, rooting reflex is gone down or is disappeared, suck loss for reaction or the head CT performance low-density shadow picture that goes down, to have or " department of pediatrics is through oxygen uptake for normal without subarachnoid hemorrhage prestige, reduce intracranial pressure, the Comprehensive Treatment village life signs such as brain cell nutrient drug are stablized, suck the breast, after sob is normal, have a medical check-up: in high spirits can to irritant reaction, anterior fontanelle door tension force is normal or nervous, extremity muscular strength and muscular tension normally or slightly increase treatment and leave hospital for 7 days-14 days, when checking after 1 month, vomiting anterior fontanelle door tension force can be had high, extremity hypermyotonia head CT show low-density shadow and subdural effusion with or to increase prestige head CT without the ventricles of the brain normal, the child of 1 month-3 months can have drowsiness, movable few, can laugh at late, the child of 3 months-6 months can not stand up and can not sit hands and limb activity can not hold thing less, cognitive competence is poor, the child of more than 6 months just has the difference of obvious language and body language with child of the same age, what these infants had is accepting ganglioside, the treatment of brain cell nutrient drug, somely accepting rehabilitation training because of existing obvious disorder of limb ' s activity.The received treatment of Chinese herbs because effect is undesirable.
3 Therapeutic Method
L () pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20091010) is oral, 1 day 2 times, and each 0.5g, treats-3 courses for the treatment of of 1 course for the treatment of at 15 days per courses for the treatment of.
(2) therapeutic effect
All infants all reach and child of the same age's intelligence and the suitable level of limb activity through treatment all the other infants except 1 routine therapeutic effect is undesirable of 1-3 the course for the treatment of.1 undesirable example may suffer from serious gestational hypertension in its female pregnancy period relevant to following factor, namely the pregnancy period just exists this infant of malnutrition is premature labor in pregnant 7 months, low birth weight, after raw, namely brain development lags behind newborn with heavy asphyxia behind the child of the same age village, fail besides to adhere to treatment, above-mentioned situation causes the therapeutic effect of infant its female responsibility not good or not jointly, just finds that its extremity muscular tension height is walked as shears step in 1 years old time.
4 model cases
Patient king so-and-so, man, 6 months, because of " find that perpendicular head is unstable, can not stand up two weeks ", for be admitted to hospital for main suit, infant had hypoxic ischemic encephalopathy history after being born, and gives comprehensive rehabilitation training after being admitted to hospital.Soon there is respiratory tract, the digestive tract infection medical histories such as heating, watery nasal discharge, cough, poor appetite, abdominal distention, diarrhoea after being admitted to hospital in infant, cannot carry out the rehabilitation of system repeatedly, and the state of an illness is recovered slowly, and financial burden and the stress of family members are larger.Infant is with easy perspiration, and pale complexion, pale tongue, tongue is greasy in vain, and fingerprint is light.Chinese medical discrimination is that lung is insufficiency of the spleen weak, and the rule for the treatment of is invigorating the spleen to benefit the lung, benefiting QI for strengthening the superficies, and pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20091010) is oral, 1 day 2 times, each 0.5g.After taking 1 week, infant is perspired comparatively and is reduced, and food of receiving comparatively before increases; After taking first quarter moon, infant complexion is comparatively front ruddy, perspires and obviously reduces, and food of receiving is normal; After taking first quarter moon again, infant is had rosy cheeks, perspiration transference cure, does not suffer from respiratory tract, digestive tract infection again; Adhering to taking 3 months, there is not respiratory tract, digestive tract infection symptom in infant again, and after rehabilitation treatment, sb.'s illness took a favorable turn leaves hospital.Follow up a case by regular visits to half a year, rarely to catch a cold, have loose bowels.

Claims (8)

1. treat a pharmaceutical composition for cerebral palsy of children, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Lysimachia hemsleyana 1100-1200 weight portion Herba Sheareriae 800-900 weight portion stevioside 60-80 weight portion fingernail blue 500-560 weight portion Saliggenon D 40-50 weight portion.
2. a kind of pharmaceutical composition for the treatment of cerebral palsy of children according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Blue 530 weight portion Saliggenon D 45 weight portions of Lysimachia hemsleyana 1150 weight portion Herba Sheareriae 850 weight portion stevioside 70 weight portion fingernail.
3. a kind of pharmaceutical composition for the treatment of cerebral palsy of children according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of cerebral palsy of children according to claim 1, is characterized in that the treatment cerebral palsy of children medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of cerebral palsy of children, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Lysimachia hemsleyana 1100-1200 weight portion Herba Sheareriae 800-900 weight portion stevioside 60-80 weight portion fingernail blue 500-560 weight portion Saliggenon D 40-50 weight portion;
Preparation method:
(1) Lysimachia hemsleyana is got by crude drug proportioning, Herba Sheareriae, stevioside, fingernail is blue, Saliggenon D, mixing, with weight percent concentration 37% ethanol as solvent, extract at 34 DEG C of warm macerating, extraction time is 30 times, each extraction time is 4.5 hours, each solvent load is 25 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by HP-20 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting HP-20 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 81% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 95% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 95% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
6. a kind of preparation method for the treatment of the pharmaceutical composition of cerebral palsy of children according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: blue 530 weight portion Saliggenon D 45 weight portions of Lysimachia hemsleyana 1150 weight portion Herba Sheareriae 850 weight portion stevioside 70 weight portion fingernail;
Preparation method:
(1) Lysimachia hemsleyana is got by crude drug proportioning, Herba Sheareriae, stevioside, fingernail is blue, Saliggenon D, mixing, with weight percent concentration 37% ethanol as solvent, extract at 34 DEG C of warm macerating, extraction time is 30 times, each extraction time is 4.5 hours, each solvent load is 25 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by HP-20 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting HP-20 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 81% ethanol as solvent, heating and refluxing extraction 5 times, each extraction time is 1.5 hours, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by XDA-8 macroporous adsorptive resins, first wash with water, use weight percent concentration 95% alcoholic solution eluting XDA-8 macroporous adsorptive resins again, collect weight percent concentration 95% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
7. a kind of preparation method for the treatment of the pharmaceutical composition of cerebral palsy of children according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of cerebral palsy of children according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats cerebral palsy of children medicine.
CN201610047276.4A 2016-01-25 2016-01-25 Medicine composition for treating schizophrenia and preparation method thereof Withdrawn CN105560869A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610047276.4A CN105560869A (en) 2016-01-25 2016-01-25 Medicine composition for treating schizophrenia and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610047276.4A CN105560869A (en) 2016-01-25 2016-01-25 Medicine composition for treating schizophrenia and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105560869A true CN105560869A (en) 2016-05-11

Family

ID=55871881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610047276.4A Withdrawn CN105560869A (en) 2016-01-25 2016-01-25 Medicine composition for treating schizophrenia and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105560869A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106728513A (en) * 2016-12-10 2017-05-31 济南昊雨青田医药技术有限公司 It is a kind of to treat pharmaceutical composition of AIDS and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106728513A (en) * 2016-12-10 2017-05-31 济南昊雨青田医药技术有限公司 It is a kind of to treat pharmaceutical composition of AIDS and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102885912A (en) Shangxia beverage for relaxing bowels and preparation method thereof
CN101428086B (en) Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof
CN107997176A (en) A kind of stomach strengthening and digestion promoting health food for preventing children's having indigestion apocleisis
CN102885348A (en) Medlar and mulberry beverage with kidney tonifying effect and preparation method thereof
CN101961366A (en) Preparation method of malan straw extract, malan straw product, pharmaceutical composition and application thereof
CN105560869A (en) Medicine composition for treating schizophrenia and preparation method thereof
CN106668348A (en) Pharmaceutical composition for treating diabetic retinopathy
CN100551424C (en) A kind of Chinese medicine composition that is used for Dealcoholic sobering-up
CN105560322A (en) Medicine composition for treating child cerebral palsy and preparation method thereof
CN102846792B (en) Phlegm-dampness constitution composition, preparation method and applications of composition
CN105535044A (en) Medicine composition for preventing and treating encephalatrophy
CN114099616B (en) Traditional Chinese medicine composition for resisting long-endurance fatigue
CN105477071A (en) Medicine composition for treating encephalanalosis and preparation method thereof
CN106581431A (en) Medicine composition for preventing and treating amygdalitis
CN105535058A (en) Medicine composition for preventing and treating pancreatic cancer
CN105663208A (en) Drug combination for preventing and treating cirrhotic ascites and preparation method thereof
CN105616753A (en) Application of Qianlieshule preparation in preparation of drug for treating chronic atrophic gastritis and complications thereof
CN105288202A (en) Pharmaceutical composition for curing infantile cough
CN105641016A (en) Pharmaceutical composition for treating coronary heart disease
CN104826062B (en) A kind of Chinese medicine compound for the treatment of neonatal jaundice
CN105287766A (en) Medicinal composition for treating children cough
CN102670957A (en) Health-care composition and preparation method and application thereof
CN106729033A (en) A kind of pharmaceutical composition for treating cold in children
CN106729031A (en) A kind of pharmaceutical composition for treating cold in children
CN106581095A (en) Medicinal composition for treating neurodermatitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160511